The European Medicines Agency (EMA) has previously stated the number of thromboembolic events associated with the jab is “no higher than the number seen in the general population”.
The MHRA has added clots remain “extremely rare” among those who have had the jab.
Regardless, they have advised healthcare personnel to administer the AstraZeneca vaccine only when “benefits from the protection from COVID-19 infection outweighs potential risks”.
Related Posts
Those receiving the jab should also stay aware of the symptoms of CVST, a potentially fatal condition.
